Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

被引:842
作者
Noguera-Troise, Irene [1 ]
Daly, Christopher [1 ]
Papadopoulos, Nicholas J. [1 ]
Coetzee, Sandra [1 ]
Boland, Pat [1 ]
Gale, Nicholas W. [1 ]
Lin, Hsin Chieh [1 ]
Yancopoulos, George D. [1 ]
Thurston, Gavin [1 ]
机构
[1] Regeneron Pharmaceut Inc, Res Labs, Tarrytown, NY 10591 USA
关键词
D O I
10.1038/nature05355
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumour growth requires accompanying expansion of the host vasculature, with tumour progression often correlated with vascular density. Vascular endothelial growth factor (VEGF) is the best-characterized inducer of tumour angiogenesis. We report that VEGF dynamically regulates tumour endothelial expression of Delta-like ligand 4 (Dll4), which was previously shown to be absolutely required for normal embryonic vascular development. To define Dll4 function in tumour angiogenesis, we manipulated this pathway in murine tumour models using several approaches. Here we show that blockade resulted in markedly increased tumour vascularity, associated with enhanced angiogenic sprouting and branching. Paradoxically, this increased vascularity was non-productive - as shown by poor perfusion and increased hypoxia, and most importantly, by decreased tumour growth - even for tumours resistant to anti-VEGF therapy. Thus, VEGF-induced Dll4 acts as a negative regulator of tumour angiogenesis; its blockade results in a striking uncoupling of tumour growth from vessel density, presenting a novel therapeutic approach even for tumours resistant to anti-VEGF therapies.
引用
收藏
页码:1032 / 1037
页数:6
相关论文
共 34 条
[1]   Notch signaling: Cell fate control and signal integration in development [J].
Artavanis-Tsakonas, S ;
Rand, MD ;
Lake, RJ .
SCIENCE, 1999, 284 (5415) :770-776
[2]   Angiogenesis in life, disease and medicine [J].
Carmeliet, P .
NATURE, 2005, 438 (7070) :932-936
[3]   Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].
Casanovas, O ;
Hicklin, DJ ;
Bergers, G ;
Hanahan, D .
CANCER CELL, 2005, 8 (04) :299-309
[4]   Dosage-sensitive requirement for mouse D114 in artery development [J].
Duarte, A ;
Hirashima, M ;
Benedito, R ;
Trindade, A ;
Diniz, P ;
Bekman, E ;
Costa, L ;
Henrique, D ;
Rossant, J .
GENES & DEVELOPMENT, 2004, 18 (20) :2474-2478
[5]   Vascular endothelial growth factor as a target for anticancer therapy [J].
Ferrara, N .
ONCOLOGIST, 2004, 9 :2-10
[6]  
Folkman J, 1992, Semin Cancer Biol, V3, P65
[7]   Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development [J].
Gale, NW ;
Dominguez, MG ;
Noguera, I ;
Pan, L ;
Hughes, V ;
Valenzuela, DM ;
Murphy, AJ ;
Adams, NC ;
Lin, HC ;
Holash, J ;
Thurston, G ;
Yancopoulos, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (45) :15949-15954
[8]   Notch signaling during vascular development [J].
Gridley, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (10) :5377-5378
[9]   A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling [J].
Hicks, C ;
Ladi, E ;
Lindsell, C ;
Hsieh, JJD ;
Hayward, SD ;
Collazo, A ;
Weinmaster, G .
JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 68 (06) :655-667
[10]   VEGF-Trap: A VEGF blocker with potent antitumor effects [J].
Holash, J ;
Davis, S ;
Papadopoulos, N ;
Croll, SD ;
Ho, L ;
Russell, M ;
Boland, P ;
Leidich, R ;
Hylton, D ;
Burova, E ;
Ioffe, E ;
Huang, T ;
Radziejewski, C ;
Bailey, K ;
Fandl, JP ;
Daly, T ;
Wiegand, SJ ;
Yancopoulos, GD ;
Rudge, JS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11393-11398